Stevanato Group Secures €200 Million Financing from BNL BNP Paribas, CDP, and Banco BPM to Fund CAPEX Investments

Stevanato Group has secured €200 million in financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to fund ongoing capital expenditure investments in Italy and the US. The financing will support capacity expansion and commercial production to meet customers' growing biologics programs. CDP has committed €50 million, while BNL BNP Paribas and Banco BPM have provided €100 million and €50 million, respectively. The funding will bolster Stevanato Group's capacity expansion efforts and support its long-term growth objectives.

Stevanato Group, a global leader in drug containment, drug delivery, and diagnostic solutions, has secured €200 million in financing from BNL BNP Paribas, Cassa Depositi e Prestiti (CDP), and Banco BPM. This funding will support the company's ongoing capital expenditure (CAPEX) projects in Italy and the United States, aimed at expanding manufacturing capacity and scaling commercial production to meet the growing demand for biologics programs.

The financing agreements include €50 million from CDP to enhance the production of pre-filled syringes and set up future capacity for ready-to-use (RTU) cartridges at Stevanato Group's Italian plant in Cisterna di Latina. BNL BNP Paribas has provided €100 million, and Banco BPM has contributed €50 million, both aimed at scaling pre-filled syringe production at the company's facilities in North America (Indiana) and Italy, as well as completing the ongoing construction for device manufacturing in Fishers.

Marco Dal Lago, Chief Financial Officer of Stevanato Group, stated, "These agreements are an important element of our financial strategy, allowing us to capitalize on robust customer demand and support our long-term growth objectives. We are committed to supporting our customers' biopharmaceutical programs with our integrated solutions across the pharmaceutical value chain."

Gianluca Mariani, Head of Industrial Manufacturing, Large Corporate Banking at BNL BNP Paribas, highlighted, "Our support for Stevanato Group reflects our commitment to partnering with companies that invest in innovation, sustainability, and global expansion. Stevanato Group is a leading example of excellence in its sector, and our goal is to make our domestic and international platforms available to contribute to the growing ambitions of the Company in the coming years."

Marco Roberto Pessione, Head of Corporate Coverage at CDP, expressed, "We are proud to once again support the growth plans of Stevanato Group, a leading Italian company active in the pharmaceutical sector, which is strategic for the Country. We firmly believe in the value of companies that invest in research, quality, and sustainable development, and that make a tangible contribution to the growth of the national economy. We remain committed to standing alongside these businesses, providing effective financial instruments to support their growth and consolidation plans both in Italy and internationally."

Enrico Lemmo, Head of Corporate Banking North-East at Banco BPM, noted, "We are proud to support a company like Stevanato Group, a symbol of Italian industrial excellence worldwide, in its solid and innovation-driven growth journey. This financing reflects our commitment to backing projects that create value locally while strengthening the international competitiveness of Italian enterprises."

This funding will bolster Stevanato Group's capacity expansion efforts and support its long-term growth objectives, positioning it to meet and exceed the demands of its customers in the growing biologics market.

References:
[1] https://www.businesswire.com/news/home/20250723635774/en/Stevanato-Group-Secures-%E2%82%AC200-Million-in-Financing-from-BNL-BNP-Paribas-Cassa-Depositi-e-Prestiti-and-Banco-BPM-to-Fund-Ongoing-CAPEX-Investments-in-Italy-and-the-U.S.
[2] https://www.stocktitan.net/news/STVN/stevanato-group-secures-200-million-in-financing-from-bnl-bnp-ma6wtcknto7y.html